AbClon Inc.
Financials
Valuation Metrics
AbClon Inc.'s Market Cap is ₩3669B. At end of 2025 it was ₩8480B. Ranked #543 of 2,405 in KR market (top 23%), #214 of 1,627 on KOSDAQ (top 13%), #56 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 366.92B KRW | KR#543/2,405 Sec#56/231 |
| Revenue | 5.31B KRW | KR#2,322/2,405 Sec#194/231 |
| Net Income | -17.30B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 64.50B KRW | KR#2,056/2,405 Sec#176/231 |
| Net Assets | 53.07B KRW | KR#1,865/2,405 Sec#159/231 |
| Employees | 63 | KR#1,932/2,405 Sec#171/231 |
| Value | ||
| P/B | 6.91x | KR#2,311/2,405 Sec#202/231 |
| P/S | 69.13x | KR#2,369/2,405 Sec#204/231 |
| FCF Yield | -3.93% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -32.60% | KR#2,192/2,405 Sec#182/231 |
| ROA | -26.82% | KR#2,280/2,405 Sec#194/231 |
| Op. Margin | -336.22% | KR#2,334/2,405 Sec#196/231 |
| Revenue Growth | 75.02% | KR#127/2,405 Sec#20/231 |
| Financial Health | ||
| Debt Ratio | 21.54% | KR#401/2,405 Sec#49/231 |
| Total Debt | 7.00B KRW | KR#1,712/2,405 Sec#159/231 |
| FCF | -14.42B KRW | KR#1,800/2,405 Sec#167/231 |
| Cash | 30.38B KRW | KR#1,005/2,405 Sec#68/231 |
| Current Ratio | 3.89x | KR#398/2,405 Sec#63/231 |
| Performance | ||
| 1Y Return | -15.25% | KR#1,132/2,405 Sec#78/231 |
| 1M Return | -34.09% | KR#2,292/2,405 Sec#223/231 |
| From 52W High | -80.80% | KR#2,301/2,405 Sec#211/231 |
| 1Y MDD | -81.12% | KR#2,296/2,405 Sec#207/231 |
| Trading | ||
| Volume | 60,002 shares | KR#857/2,405 Sec#94/231 |
| Trading Value | 1.11B KRW | KR#566/2,405 Sec#58/231 |
| Foreign Own. | 7.73% | KR#574/2,405 Sec#47/231 |
| Per Share | ||
| EPS | -867 KRW | KR—/2,405 Sec—/231 |
| BPS | 2,660 KRW | KR#1,938/2,405 Sec#152/231 |
Company Info
AbClon, established in 2010 and headquartered in Guro-gu, Seoul, is a bio-venture focused on antibody new drug development, manufacturing, and sales, specially listed on KOSDAQ in 2017. The company utilizes platforms such as NEST, AffiMab, and CAR-T, maintaining a research network with Atlas in Sweden. AbClon licensed AC101, developed with NEST technology, to Shanghai Henlius, and its CAR-T therapeutic AT101 is currently in Phase 2 clinical trials. It aims to strengthen its immune cell therapy presence through a partnership with Chong Kun Dang in 2025.